HB 2453
In CommitteeHouse
Psychiatric pharmacists
Concerning psychiatric pharmacists.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill formally recognizes and defines "board-certified psychiatric pharmacists" as qualified mental health professionals who can participate in court-ordered outpatient treatment for people with behavioral health disorders. It allows them to sign petitions, provide clinical declarations, and help authorize certain treatments—including involuntary antipsychotic medications—under existing involuntary commitment and assisted outpatient treatment laws.
- Adds a new definition for "board-certified psychiatric pharmacist"—a pharmacist licensed under chapter 18.64 RCW who holds a psychiatric pharmacy specialty certification.
- Authorizes "board-certified psychiatric pharmacists" to sign petitions and provide declarations for assisted outpatient treatment (AOT), alongside physicians, physician assistants, and psychiatric advanced practice nurses.
- Expands the list of qualified professionals who can sign AOT petitions and provide clinical declarations to include board-certified psychiatric pharmacists in multiple sections (RCW 71.05.148, 71.05.230, and 71.05.585).
- Clarifies that board-certified psychiatric pharmacists may participate in authorizing involuntary antipsychotic medication under less restrictive alternative treatment, when concurring medical opinions are required.
- Includes provisions for sunset and contingent effective dates: Sections 3, 5, and 7 expire June 30, 2027; Sections 4, 6, and 8 take effect June 30, 2027.
Who is affected
- Individuals with behavioral health disorders — People with behavioral health disorders who may be ordered to receive outpatient treatment instead of being involuntarily committed to inpatient care, especially those with repeated hospitalizations or violent behavior related to their condition.
- Board-certified psychiatric pharmacists — Can now sign petitions and provide declarations for assisted outpatient treatment, expanding the range of qualified professionals who can initiate or support court-ordered outpatient treatment.
- Behavioral health service providers and treatment facilities — Hospitals, behavioral health providers, and treatment facilities that may be asked to provide or coordinate outpatient treatment services under court orders, and must meet certification or licensing requirements.
- Courts and judicial personnel — Courts and court personnel who must process petitions, hold hearings, and issue orders for assisted outpatient treatment, including ensuring due process rights for respondents.
Pro/Con Analysis
Potential Benefits (2)
Allowing board-certified psychiatric pharmacists to sign AOT petitions and provide clinical declarations expands access to timely mental health interventions—especially in underserved areas where psychiatrist shortages are severe. Pharmacists are often more accessible than physicians in community settings, potentially reducing delays in care and preventing hospitalizations.
HealthcarePeopleRef: RCW 71.05.148(2)(f), RCW 71.05.230(4)(a)(i), RCW 71.05.585(3)Permitting pharmacists to concur on involuntary antipsychotic medication authorizations increases continuity of care during transitions from inpatient to outpatient settings. This may reduce treatment gaps and improve adherence for individuals with severe mental illness, lowering rates of relapse and crisis.
HealthcarePeopleRef: RCW 71.05.585(3)
Potential Concerns (3)
Expanding authority to initiate involuntary outpatient treatment to board-certified psychiatric pharmacists—without requiring supervision or co-signature from a physician—lowers the threshold for state intervention in individual liberty. While pharmacists are licensed clinicians, they do not have independent diagnostic authority or medical training equivalent to physicians, raising concerns about due process and the risk of overreach in civil commitment.
Rights & LibertiesPeopleRef: RCW 71.05.148(5)(b), added to definitions in RCW 71.05.020(64)Authorizing pharmacists to concur on involuntary antipsychotic medication decisions—especially when consent cannot be obtained—may increase risks if pharmacists lack full clinical autonomy in diagnosing psychosis or assessing medication risks. Although the bill requires a concurring opinion from another provider, in resource-constrained settings, pharmacists may be the only available qualified professional, potentially compromising safety.
Public SafetyPeopleRef: RCW 71.05.230(4)(a)(i), RCW 71.05.585(3)The bill includes a sunset date for most provisions, creating uncertainty for counties and behavioral health systems that must plan for a potentially temporary expansion of authority. This may delay long-term workforce development and infrastructure investment, especially in rural areas where mental health providers are already scarce.
Local GovernmentLean peopleRef: Sunset in Sec. 11 (June 30, 2027)
Who Is Most Affected
Individuals with severe mental illness who have historically struggled with treatment access or adherence may benefit from earlier, more accessible outpatient interventions—potentially reducing hospitalizations and incarceration. However, some may perceive the expansion of involuntary authority as a threat to autonomy, especially if pharmacists lack long-term therapeutic relationships with them.
Board-certified psychiatric pharmacists gain formal recognition and expanded clinical authority, which may improve job satisfaction and retention in public mental health settings. However, they assume greater legal liability and may face role confusion in multidisciplinary teams where physicians traditionally lead treatment decisions.
Behavioral health providers may benefit from increased staffing flexibility and reduced reliance on overburdened psychiatrists. However, they must invest in training, credentialing, and systems to support pharmacist-led AOT petitions, which may strain already limited resources.
Courts may benefit from more consistent petition filings and potentially faster processing of AOT cases, as pharmacists are often available in emergency departments and community clinics. However, judges may face increased burden verifying pharmacist qualifications and ensuring due process compliance.